Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial

Fig. 1

Study Schema. SABR = stereotactic ablative radiotherapy; W = weeks; M = months. *histology dichotomized as prostrate, breast, or renal vs. all others. **disease free interval defined as time from diagnosis of primary tumor until first detection of metastatses, and dichotomized as ≤2 vs. > 2 years

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us